1. Scrip
  2. >>Conferences
  3. >>ASCO

Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

 
• By Alaric DeArment

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

3d illustration of T cells or cancer cells
Fate Therapeutics presented early data at ASCO on its NK cell therapy program • Source: Shutterstock

Fate Therapeutics, Inc.’s natural killer (NK) cell therapy FT516 is still early and requires longer follow-up to determine if the responses it has produced in non-Hodgkin lymphoma (NHL) patients when combined with Roche Holding AG’s Rituxan (rituximab) are durable. Still, its early data gives a positive sign about the potential of the company’s pipeline, as well as FT516’s applicability beyond NHL and other hematological cancers.

The company presented Phase I data on FT516/Rituxan in a poster at the American Society of Clinical Oncology meeting, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from Conferences